4',6,7-三羟异黄酮
4',6,7-三羟异黄酮 性质
| 熔点 | >280℃ |
|---|---|
| 沸点 | 587.1±50.0 °C(Predicted) |
| 密度 | 1.548±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | 溶于二甲基甲酰胺 |
| 形态 | 粉末晶体 |
| 酸度系数(pKa) | 6.85±0.20(Predicted) |
| 颜色 | 淡黄色至棕色至深绿色 |
| 生物来源 | synthetic |
| 主要应用 | 临床研究 常规分析检测 生命科学和生物制药 代谢组学 |
| InChI | InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)11-7-20-14-6-13(18)12(17)5-10(14)15(11)19/h1-7,16-18H |
| InChIKey | GYLUFQJZYAJQDI-UHFFFAOYSA-N |
| SMILES | C1=CC(=CC=C1C2=COC3=CC(=C(C=C3C2=O)O)O)O |
| LogP | 2.170 (est) |
| CAS 数据库 | 17817-31-1(CAS DataBase Reference) |
4',6,7-三羟异黄酮 用途与合成方法
|
CDK1
|
CDK2
|
PKC
|
Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppesses anchorage-dependent growth of HCT-116 and DLD1 cells in a dose- and time-dependent manner without cytotoxicity . Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) suppresses CDK1 activity in a dose-dependent manner and inhibits CDK2 activity in HCT-116 cells. Desmethylglycitein (4',6,7-Trihydroxyisoflavone)(0-100 μM; 24-72 hours) induces cell cycle arrest at the S and G2/M phases, the percentage of cells in S phase is higher in the 100 μM 6,7,4′-THIF-treated group, and the same pattern is observed in G2/M phase (29.5% versus 19.1% ) .
Cell Viability Assay
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 12.5, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Inhibited anchorage-dependent and -independent growth of HCT-116 cells. |
Western Blot Analysis
| Cell Line: | HCT-116 and DLD1 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 48 hours |
| Result: | Inhibited CDK1,CDK2 expression. |
Cell Cycle Analysis
| Cell Line: | HCT-116 cells |
| Concentration: | 0, 25, 50 or 100 μM |
| Incubation Time: | 24, 48 or 72 hours |
| Result: | Induces cell cycle arrest of HCT-116 cells at S and G2/M phases. |
Desmethylglycitein (4',6,7-Trihydroxyisoflavone) (intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days) suppresses tumor development in mice and serves as an effective anticancer treatment with the potential to inhibit or delay the tumorigenicity of HCT-116 cells in an in vivo system.
| Animal Model: | Female athymic nude mice subcutaneously injected with HCT-116 cells |
| Dosage: | 5 or 25 mg/kg |
| Administration: | Intraperitoneally injection; 5 or 25 mg/kg; once daily; 20 days |
| Result: | Decreased tumor growth, volume and weight of HCT-116 xenografts. |
4',6,7-三羟异黄酮 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2026-09-15 | HY-N5072 | 4',6,7-三羟异黄酮 | 17817-31-1 | 5mg | 300 |
| 2026-09-15 | HY-N5072 | 4',6,7-三羟异黄酮 | 17817-31-1 | 10 mM * 1 mLin DMSO | 330 |
